References
1 Buhleier, E, Wehner, W, Vögtle, F. Cascade‐ and nonskid‐chain‐like syntheses of molecular cavity topologies. Synthesis 1978, 2:155–158.
2 Tomalia, DA, Baker, H, Dewald, J, Hall, M, Kallos, G, Martin, S, Roeck, J, Ryder, J, Smith, P. A new class of polymers: starburst‐dendritic macromolecules. Polym J 1985, 17:117–132.
3 Klajnert, B, Bryszewska, M. Dendrimers: properties and applications. Acta Biochim Pol 2001, 48:199–208.
4 Svenson, S, Tomalia, DA. Dendrimers in biomedical applications—reflections on the field. Adv Drug Deliv Rev 2005, 57:2106–2129.
5 Nanjwade, BK, Bechra, HM, Derkar, GK, Manvi, FV, Nanjwade, VK. Dendrimers: emerging polymers for drug‐delivery systems. Eur J Pharm Sci 2009, 38:185–196.
6 Maraval, V, Pyzowski, J, Caminade, AM, Majoral, JP. “Lego” chemistry for the straightforward synthesis of dendrimers. J Org Chem 2003, 68:6043–6046.
7 Wu, P, Feldman, AK, Nugent, AK, Hawker, CJ, Scheel, A, Voit, B, Pyun, J, Fréchet, JMJ, Sharpless, KB, Fokin, VV. Efficiency and fidelity in a click‐chemistry route to triazole dendrimers by the copper(I)‐catalyzed ligation of azides and alkynes. Angew Chem Int Ed Engl 2004, 43:3928–3932.
8 Tomalia, DA. Birth of a new macromolecular architecture: dendrimers as quantized building blocks for nanoscale synthetic organic chemistry. Aldrichim Acta 2004, 37:39–57.
9 Jang, WD, Kamruzzaman Selim, KM, Lee, CH, Kang, IK. Bioinspired application of dendrimers: from bio‐mimicry to biomedical applications. Prog Polym Sci 2008, 34:1–23.
10 Jain, K, Kesharwani, P, Gupta, U, Jain, NK. Dendrimer toxicity: let`s meet the challenge. Int J Pharm 2010, 394:122–142.
11 Rojo, J, Delgado, R. Dendrimers and dendritic polymers as anti‐infective agents: new antimicrobial strategies for therapeutic drugs. Anti‐Infect Agents Med Chem 2007, 6:151–174.
12 Oliveira, JM, Salgado, AJ, Sousa, N, Mano, JF, Reis, RL. Dendrimers and derivatives as a potential therapeutic tool in regenerative medicine strategies—a review. Prog Polym Sci 2010, 35:1163–1194.
13 Menjoge, AR, Kannan, RM, Tomalia, DA. Dendrimer‐based drug and imaging conjugates: design considerations for nanomedical applications. Drug Discov Today 2010, 15:171–185.
14 Gunaseelan, S, Gunaseelan, K, Deshmukh, M, Zhang, X, Sinko, PJ. Surface modifications of nanocarriers for effective intracellular delivery of anti‐HIV drugs. Adv Drug Deliv Rev 2010, 62:518–531.
15 Sharma, P, Garg, S. Pure drug and polymer based nanotechnologies for the improved solubility, stability, bioavailability and targeting of anti‐HIV drugs. Adv Drug Deliv Rev 2010, 62:491–502.
16 Ting, CL, Wang, ZG. Interactions of a charged nanoparticle with a lipid membrane: implications for gene delivery. Biophys J 2011, 100:1288–1297.
17 Landers, JJ, Cao, Z, Lee, I, Piehler, LT, Myc, PP, Myc, A, Hamouda, T, Galecki, AT, Baker Jr, JR. Prevention of influenza pneumonitis by sialic acid‐conjugated dendritic polymers. J Infect Dis 2002, 186:1222–1230.
18 Tsvetkov, DE, Cheshev, PE, Tuzikov, AB, Chinarev, AA, Pazynina, GV, Sablina, MA, Gambaryan, AS, Bovin, NV, Rieben, R, Shashkov, AS, Nifant`ev, NE. Neoglycoconjugates based on dendrimer poly(aminoamides). Russ J Bioorg Chem 2002, 28:470–486.
19 Oka, H, Onaga, T, Koyama, T, Guo, CT, Suzuki, Y, Esumi, Y, Hatano, K, Terenuma, D, Matsuoka, K. Sialyl
α(2→3) lactose clusters using carbosilane dendrimer core scaffolds as influenza hemagglutinin blockers. Bioorg Med Chem Lett 2008, 18:4405–4408.
20 Sakamoto, JI, Koyama, T, Miyamoto, D, Yingsakmongkon, S, Hidari, KIP, Jampangern, W, Suzuki, T, Suzuki, Y, Esumi, Y, Nakamura, T, et al. Systematic syntheses of influenza neuraminidase inhibitors: a series of carbosilane dendrimers uniformly functionalized with thioglycoside‐type sialic acid moieties. Bioorg Med Chem 2009, 17:5451–5464.
21 Sakamoto, JI, Koyama, T, Miyamoto, D, Yingsakmongkon, S, Hidari, KIP, Jampangern, W, Suzuki, T, Suzuki, Y, Esumi, Y, Nakamura,, et al. Thiosialoside clusters using carbosilane dendrimer core scaffolds as a new class of influenza neuraminidase inhibitors. Bioorg Med Chem 2007, 17:717–721.
22 Lasala, F, Arce, E, Otero, JR, Rojo, J, Delgado, R. Mannosyl glycodendritic structure inhibits DC‐SIGN‐mediated Ebola virus infection in cis and in trans. Antimicrob Agents Chemother 2003, 47:3970–3972.
23 Gong, Y, Matthews, B, Cheung, D, Tam, T, Gadawski, I, Leung, D, Holan, G, Raff, J, Sacks, S. Evidence of dual sites of action of dendrimers: SPL‐2999 inhibits both virus entry and late stages of herpes simplex virus replication. Antiviral Res 2002, 55:319–329.
24 Patton, DL, Cosgrove Sweeny, YT, McCarthy, TD, Hillier, SL. Preclinical safety and efficacy assessments of dendrimer‐based (SPL7013) microbicide gel formulations in a nonhuman primate model. Antimicrob Agents Chemother 2006, 50:1696–1700.
25 O`Loughlin, J, Millwood, IY, McDonald, HM, Price, CF, Kaldor, JM, Paull, JR. Safety, tolerability, and pharmacokinetics of SPL7013 gel (VivaGel): a dose ranging, phase I study. Sex Transm Dis 2010, 37:100–104.
26 Gong, E, Matthews, B, McCarthy, T, Chu, J, Holan, G, Raff, J, Sacs, S. Evaluation of dendrimer SPL7013, a lead microbicide candidate against herpes simplex viruses. Antiviral Res 2005, 68:139–146.
27 Tyssen, D, Henderson, SA, Johnson, A, Sterjovski, J, Moore, K, La, J, Zanim, M, Sonza, S, Karellas, P, Giannis, MP, et al. Structure activity relationship of dendrimer microbicides with dual action antiviral activity. PLoS One 2010, 5:e12309.
28 Luganini, A, Nicoletto, SF, Pizzuto, L, Pirri, G, Giuliani, A, Landolfo, S, Gribaudo, G. Inhibition of Herpes simplex virus type 1 and type 2 infections by peptide‐derivatized dendrimers. Antimicrob Agents Chemother 2011, 55:3231–3239.
29 Luganini, A, Giuliani, A, Pirri, G, Pizzuto, L, Landolfo, S, Gribaudo, G. Peptide‐derivatized dendrimers inhibit human cytomegalovirus infection by blocking virus binding to cell surface heparan sulfate. Antiviral Res 2010, 85:532–540.
30 Donalisio, M, Rusnati, M, Civra, A, Bugatti, A, Allemand, D, Pirri, G, Giuliani, A, Landolfo, S, Lembo, D. Identification of a dendrimeric heparan sulfate‐binding peptide that inhibits infectivity of genital types of human papillomaviruses. Antimicrob Agents Chemother 2010, 54:4290–4299.
31 Blanzat, M, Turrin, CO, Aubertin, AM, Couturier‐Vidal, C, Caminade, AM, Majoral, JP, Rico‐Lattes, I, Lattes, A. Dendritic catanionic assemblies: in vitro anti‐HIV activity of phosphorus‐containing dendrimers bearing gal
β1cer analogues. Chembiochem 2005, 6: 2207–2213.
32 Kelesidis, T, Humphries, R, Uslan, DZ, Pegues, D. De novo daptomycin‐nonsusceptible enterococcal infections. Emerging Infect Dis 2012, 18:674–676.
33 Cordina, C, Hill, R, Deshpande, A, Hood, H, Inkster, T. Tigecycline‐resistant
Enterococcus faecalis associated with omeprazole use in surgical patient. J Antimicriob Chemoth 2012, 67:1806–1807.
34 Calabretta, MK, Kumar, A, McDermott, AM, CCai, C. Antibacterial activities of poly(amidoamine) dendrimers terminated with amino and poly(ethylene glycol) groups. Biomacromolecules 2007, 8:1807–1811.
35 Fey, PD. Modality of bacterial growth presents unique targets: how do we treat biofilm‐mediated infections? Curr Opin Microbiol 2010, 13:610–615.
36 Rasines, B, Hernández‐Ros, JM, de las Cuevas, N, Copa‐Patiño, JL, Soliveri, J, Muñez‐Fernandez, MA, Gómez, R, de la Mata, FJ. Water‐stable ammonium‐terminated carbosilane dendrimers as efficient antibacterial agents. Dalton Trans 2009, 40:8704–8713.
37 Gajbhiye, V, Kumar, PV, Tekade, RK, Jain, NK. Pharmaceutical and biomedical potential of PEGylated dendrimers. Curr Pharm Des 2007, 13:415–429.
38 Ziemba, B, Janaszewska, A, Ciepluch, K, Krotewicz, M, Fogel, WA, Appelhans, D, Voit, B, Bryszewska, M, Klajnert, B. In vivo toxicity of poly(propyleneimine) dendrimers. J Biomed Mater Res A 2011, 99:261–268.
39 Kolhatkar, RB, Kitchens, KM, Swaan, PW, Ghandehari, H. Surface acetylation of polyamidoamine (PAMAM) dendrimers decreases cytotoxicity while maintaining membrane permeability. Bioconjugate Chem 2007, 18:2054–2060.
40 Medina, SH, El‐Sayed, MEH. Dendrimers as carriers for delivery of chemotherapeutic agents. Chem Rev 2009, 109:3141–3157.
41 Wang, W, Xiong, W, Wan, J, Sun, X, Xu, H, Yang, H. The decrease of PAMAM dendrimer‐induced cytotoxicity by PEGylation via attenuation of oxidative stress. Nanotechnology 2009, 20:105103.
42 Waite, CL, Sparks, SM, Uhrich, KE, Roth, CM. Acetylation of PAMAM dendrimers for cellular delivery of siRNA. BMC Biotechnol 2009, 9:9–38.
43 Kang, C, Yuan, X, Li, F, Pu, P, Yu, S, Shen, C, Zhang, Z, Zhang, Y. Evaluation of folate‐PAMAM for the delivery of antisense oligonucleotides to rat C6 glioma cells in vitro and in vivo. J Biomed Mater Res 2010, 93:585–594.
44 de Paz, JL, Noti, C, Böhm, F, Werner, S, Seeberger, PH. Potentiation of fibroblast growth factor activity by synthetic heparin oligosaccharide glycodendrimers. Chem Biol 2007, 14:879–887.
45 Ghaemmaghami, S, Ullman, J, Ahn, M, St Martin, S, Prusiner, SB. Chemical induction of misfolded prion protein conformers in cell culture. J Biol Chem 2010, 285:10415–10423.
46 Tomalia, DA, Fréchet, JMJ. Discovery of dendrimers and dendritic polymers: a brief historical perspective. J Polym Sci Part A Polym Chem 2001, 40:2719–2728.
47 Boas, U, Christensen, JB, Heegaard, PMH. Dendrimers: design, synthesis and chemical properties. J Mater Chem 2006, 16:3785–3798.
48 Bhadra, D, Yadav, AK, Bhadra, S, Jain, NK. Glycodendrimeric nanoparticulate carriers of primaquine phosphate for liver targeting. Int J Pharm 2005, 295:221–233.
49 Kesharwani, P, Tekade, RK, Gajbhiye, V, Jain, K, Jain, NK. Cancer targeting potential of some ligand‐anchored poly(propylene imine) dendrimers: a comparison. Nanomed Nanotech Biol Med 2011, 7:295–304.
50 Cordes, H, Boas, U, Olsen, P, Heegaard, PMH. Guanidino‐ and urea‐modified dendrimers as potent solubilizers of misfolded prion protein aggregates under non‐cytotoxic conditions. Dependence on dendrimer generation and surface charge. Biomacromolecules 2007, 8:3578–3583.
51 Sadler, K, Tam, JP. Peptide dendrimers: applications and synthesis. Mol Biotechnol 2002, 90:195–229.
52 Denkewalter, RG, Kolc, J, Lukasavage, WJ. Macromolecular highly branched homogeneous compound based on lysine units. US Patent 4289872, 1981.
53 Posnett, DN, McGrath, H, Tam, JP. A novel method for producing anti‐peptide antibodies. Production of site‐specific antibodies to the T cell antigen receptor beta‐chain J Biol Chem 1988, 263:1719–1725.
54 Tam, JP. Synthetic peptide vaccine design: synthesis and properties of a high‐density multiple antigenic peptide system. Proc Natl Acad Sci USA 1988, 85:5409–5413.
55 Gu, ZW, Luo, K, She, WC, Eu, Y, He, B. New‐generation biomedical materials: peptide dendrimers and their application in biomedicine. Sci China Chem 2010, 53:458–478.
56 Al‐Jamal, KT, Al‐Jamal, WT, Akerman, S, Podesta, JE, Yilmazer, A, Turton, JA, Bianco, A, Vargesson, N, Kanthou, C, Florence, AT, et al. Systemic antiangiogenic activity of cationic poly‐L‐lysine dendrimer delays tumor growth. Proc Natl Acad Sci USA 2010, 107:3966–3971.
57 Rupp, R, Rosenthal, SL, Stanberry, LR. VivaGel (SPL7013 Gel): a candidate dendrimer—microbicide for the prevention of HIV and HSV infection. Int J Nanomed 2007, 2:561–566.
58 Telwatte, S, Moore, K, Johnson, A, Tyssen, D, Sterjovski, J, Aldunate, M, Gorry, PR, Ramsland, PA, Lewis, GR, Paull, JRA, et al. Virucidal activity of the dendrimer microbicide SPL7013 against HIV‐1. Antiviral Res 2011, 90:195–199.
59 http://clinicaltrials.gov/ct2/show/NCT01437722 (Accessed March 30, 2012).
60 http://clinicaltrials.gov/ct2/show/NCT01201057 (Accessed March 30, 2012).
61 http://clinicaltrials.gov/ct2/results?term=vivagel (Accessed March 30, 2012).
62 Frey, H, Schlenk, C. Silicon‐based dendrimers. Top Curr Chem 2000, 210:69–129.
63 Roovers, J, Ding, J. %22Carbosilane dendrimrs.%22 In: Advances in Silicone Science, Silicon Containing Dendritic Polymers, vol. 2. Dordrecht:
Springer; 2009, 31–74.
64 Ortega, P, Serramía, J, Muñoz‐Fernández, A, de la Mata, FJ, Gómez, R. Globular carbosilane dendrimers with mannose groups at the periphery: synthesis, characterization and toxicity in dendritic cells. Tetrahedron 2010, 66:3326–3331.
65 Shcharbin, D, Pedziwiatr, E, Nowacka, O, Kumar, M, Zaborski, M, Ortega, P, de la Mata, FJ, Gómez, R, Muñez‐Fernandez, MA, Bryszewska, M. Carbosilane dendrimers NN8 and NN16 form a stable complex with siGAG1. Colloids Surf B Biointerfaces 2011, 83:388–391.
66 Weber, N, Ortega, P, Clemente, MI, Shchlarbin, D, Bryszewska, M, de la Mata, FJ, Gómez, R, Muñez‐Fernandez, MA. Characterization of carbosilane dendrimers as effective carriers of siRNA to HIV‐infected lymphocytes. J Control Rel 2008, 132:55–64.
67 Caminade, AM, Majoral, JP. Water‐soluble phosphorus‐containing dendrimers. Prog Polym Sci 2005, 30:491–505.
68 Turrin, CO, Maraval, V, Leclaire, J, Dantras, E, Lacabanne, C, Caminade, AM, Majoral, JP. Surface, core, and structure modifications of phosphorus‐containing dendrimers. Influence on the thermal stability. Tetrahedron 2003, 59:3965–3973.
69 Ionov, M, Gardikis, K, Wróbel, D, Hatziantoniou, S, Mourelatou, H, Majoral, JP, Klajnert, B, Bryszewska, M, Demetzos, C. Interaction of cationic phosphorus dendrimers (CPD) with charged and neutral lipid membranes. Colloids Surf B Biointerfaces 2011, 82:8–12.
70 Wrobel, D, Ionov, M, Gardikis, K, Demetzos, C, Majoral, JP, Palecz, B, Klajnert, B, Bryszewska, M. Interactions of phosphorus‐containing dendrimers with liposomes. Biochim Biophys Acta 2011, 1811:221–226.
71 Padié, C, Maszewska, M, Majchrzak, K, Nawrot, B, Caminade, AM, Majoral, JP. Polycationic phosphorus dendrimers: synthesis, characterization, study of cytotoxicity, complexation of DNA, and transfection experiments. New J Chem 2009, 33:318–326.
72 Shakhbazau, AV, Shcharbin, DG, Goncharova, NV, Seviaryn, IN, Kosnacheva, SM, Kartel, NA, Bryszewska, M, Majoral, JP, Potapnev, MP. Neurons and stromal stem cells as targets for polycation‐mediated transfection. Bull Exp Biol Med 2011, 151:126–129.
73 Ottaviani, MF, Mazzeo, R, Cangiotti, M, Fiorani, L, Majoral, JP, Caminade, AM, Pedziwiatr, E, Bryszewska, M, Klajnert, B. Time evolution of aggregation process of peptides involved in neurodegenerative diseases and preventing aggregation effect of phosphorus dendrimers studied by EPR. Biomacromolecules 2010, 11:3014–3021.
74 Spataro, G, Malecaze, F, Turrin, CO, Soler, V, Duhayon, C, Elena, PP, Majoral, JP, Caminade, AM. Designing dendrimers for ocular drug delivery. Eur J Med Chem 2010, 45:326–334.
75 Mongin, O, Rouxel, C, Robin, AC, Pla‐Quintana, A, Krishna, TR, Recher, G, Tiaho, F, Caminade, AM, Majoral, JP, Blanchard‐Desce, M. Brilliant organic nanodots: novel nano‐objects for bionanophotonics. Proc SPIE‐Int Soc Opt Eng 2008, 7040:704006.
76 Solassol, J, Crozet, C, Perrier, V, Leclaire, J, Béranger, F, Caminade, AM, Meunier, B, Dormont, D, Majoral, JP, Lehmann, S. Cationic phosphorus‐containing dendrimers reduce prion replication both in cell culture and in mice infected with scrapie. J Gen Virol 2004, 85:791–799.
77 Fiore, AR, Bridges, CB, Cox, NJ. Seasonal influenza vaccines. Curr Top Microbiol Immunol 2009, 333:43–82.
78 Gamblin, SJ, Skehel, JJ. Influenza hemagglutinin and neuraminidase membrane glycoproteins. J Biol Chem 2010, 285:28403–28409.
79 Leneva, IA, Glushkov, RG, Gus`kova, TA. Drugs for chemotherapy and prophylaxis of influenza: mechanisms, efficacy, and safety. Pharm Chem J 2004, 38:8–14.
80 Kiefel, MJ, von Itzstein, M. Recent advances in the synthesis of sialic acid derivatives and sialylmimetics as biological probes. Chem Rev 2002, 102:471–490.
81 Guo, CT, Sun, X‐L, Kanie, O, Shortridge, KF, Suzuki, T, Miyamoto, D, Jwa Hidari, KI‐P, Wong, C‐H, Suzuki, Y. An O‐glycoside of sialic acid derivative that inhibits both hemagglutinin and sialidase activities of influenza viruses. Glycobiology 2002, 12:183–190.
82 Sarwar, UN, Sitar, S, Ledgerwood, JE. Filovirus emergence and vaccine development: a perspective for health care practitioners in travel medicine. Travel Med Infect Dis 2011, 9:126–134.
83 Feldmann, H, Geisbert, TW. Ebola haemorrhagic fever. Lancet 2011, 377:849–862.
84 Simmons, G, Reeves, JD, Grogan, CC, Vandenberghe, LH, Baribaud, F, Whitbeck, JC, Burke, E, Buchmeier, MJ, Soilleux, EJ, Riley, JL, et al. DC‐SIGN and DC‐SIGNR bind Ebola glycoproteins and enhance infection of macrophages and endothelial cells. Virology 2003, 305:115–123.
85 Luczkowiak, J, Sattin, S, Sutkevičiūtė, I, Reina, JJ, Sánchez‐Navarro, M, Thépaut, M, Martínez‐Prats, L, Daghetti, A, Fieschi, F, Delgado, R, et al. Pseudosaccharide functionalized dendrimers as potent inhibitors of DC‐SIGN dependent Ebola pseudotyped viral infection. Bioconjugate Chem 2011, 22:1354–1365.
86 Whitley, RJ, Roizman, B. Herpes simplex viruses: is a vaccine tenable? J Clin Invest 2002, 110:145–151.
87 Griffiths, A. Slipping and sliding: frameshift mutations in herpes simplex virus thymidine kinase and drug‐resistance. Drug Resistance Updates 2011, 14:251–259.
88 van Hal, SJ, Dwyer, DE. Herpes Simplex: Viruses and Infections. Chichester:
eLS; 2009.
89 Bernstein, DI, Stanberry, LR, Sacks, S, Ayisi, NK, Gong, YH, Ireland, J, Mumper, RJ, Holan, G, Matthews, B, McCarthy, T, et al. Evaluations of unformulated and formulated dendrimer‐based microbicide candidates in mouse and guinea pig models of genital herpes. Antimicrob Agents Chemother 2003, 47:784–788.
90 UNAIDS, Joint United Nations Programme on HIV/AIDS (UNAIDS), Report on the global AIDS epidemic, 2010.
91 Poropatich, K, Sullivan Jr, DJ. Human immunodeficiency virus type 1 long‐term non‐progressors: the viral, genetic and immunological basis for disease non‐progression. J Gen Virol 2011, 92:247–268.
92 Neumann, AK, Thompson, NL, Jacobson, K. Distribution and lateral mobility of DC‐SIGN on immature dendritic cells—implications for pathogen uptake. J Cell Sci 2008, 121:634–643.
93 Ray, N, Doms, R. HIV‐1 coreceptors and their inhibitors. Curr Top Microbiol Immunol 2006, 303:97–120.
94 Xiang, SH, Finzi, A, Pacheco, B, Alexander, K, Yuan, W, Rizzuto, C, Huang, CC, Kwong, PD, Sodroski, J. A V3 loop‐dependent gp120 element disrupted by CD4 binding stabilizes the human immunodeficiency virus envelope glycoprotein trime. J Virol 2010, 84:3147–3161.
95 Pérez‐Anes, A, Spataro, G, Coppel, Y, Moog, C, Blanzant, M, Turrin, CO, Caminade, AM, Rico‐Lattes, I, Majoral, JP. Phosphonate terminated PPH dendrimers: influence of pendant alkyl chains on the in vitro anti‐HIV‐1 properties. Org Biomol Chem 2009, 7:3491–3498.
96 Pérez‐Anes, A, Stefaniu, C, Moog, C, Majoral, JP, Blanzat, M, Turrin, CO, Caminade, AM, IRico‐Lattes, I. Multivalent catanionic GalCer analogs derived from first generation dendrimeric phosphonic acids. Bioorg Med Chem 2010, 18:242–248.
97 Han, S, Yoshida, D, Kanamoto, T, Nakashima, H, Uryu, T, Yoshida, T. Sulfated oligosaccharide cluster with polylysine core scaffold as a new anti‐HIV dendrimer. Carbohydr Polym 2010, 80:1111–1115.
98 Campo, MS, Roden, RBS. Papillomavirus prophylactic vaccines: established successes, new approaches. J Virol 2010, 84:1214–1220.
99 Crough, T, Khanna, R. Immunobiology of human cytomegalovirus: from bench to bedside. Clin Microbiol Rev 2009, 22:76–98.
100 Mercorelli, B, Lembo, D, Palú, G, Loregian, A. Early inhibitors of human cytomegalovirus: state‐of‐art and therapeutic perspectives. Pharmacol Ther 2011, 131:309–329.
101 Zhu, W, Li, J, Liang, G. How does cellular heparan sulfate function in viral pathogenicity? Biomed Environ Sci 2011, 24:81–87.
102 Bodaghi, B, Slobbe‐van Drunen, MEP, Topilko, A, Perret, E, Vossen, RCRM, van Dam‐Mieras, MCE, Zipeto, D, Virelizier, JL, LeHoang, P, Bruggeman, CA, Michelson, S. Entry of human cytomegalovirus into retinal pigment epithelial and endothelial cells by endocytosis. Invest Ophthalmol Vis Sci 1999, 40:2598–2607.
103 Horvath, CAJ, Boulet, GAV, Renoux, VM, Delvenne, PO, Bogers, JPJ. Mechanisms of cell entry by human papillomaviruses: an overview. Virol J 2010, 7:11.
104 Cars, O, Hedin, A, Heddini, A. The global need for effective antibiotics‐moving towards concerted action. Drug Resist Updates 2011, 14:68–69.
105 Rice, LB. Unmet medical needs in antibacterial therapy. Biochem Pharmacol 2006, 71:991–995.
106 Mendes, RE, Deshpande, LM, Farrell, DJ, Spanu, T, Fadda, G, Jones, RN. Assessment of linezolid resistance mechanisms among
Staphylococcus epidermidis causing bacteraemia in Rome, Italy. J Antimicrob Chemother 2010, 65:2329–2335.
107 Polcyn, P, Jurczak, M, Rajnisz, A, Solecka, J, Urbanczyk‐Lipowska, Z. Design of antimicrobially active small amphiphilic peptide dendrimers. Molecules 2009, 14:3881–3905.
108 Tam, JP, Lu, YA, Yang, JL. Antimicrobial dendrimeric peptides. Eur J Biochem 2002, 269:923–932.
109 Liu, Z, Young, AW, Hu, P, Rice, AJ, Zhou, C, Zhang, Y, Kallenbach, NR. Tuning the membrane selectivity of antimicrobial peptides by using multivalent design. ChemBioChem 2007, 8:2063–2065.
110 Hou, S, Zhou, C, Liu, Z, Youn, AW, Shi, Z, Ren, D, Kallenbach, NR. Antimicrobial dendrimer active against
Escherichia coli biofilms. Bioorg Med Chem Lett 2009, 19:5478–5481.
111 Lopez, AI, Kumar, A, Planas, MR, Li, Y, Nguyen, TV, Cai, C. Biofunctionalization of silicone polymers using poly(amidoamine) dendrimers and a mannose derivative for prolonged interference against pathogen colonization. Biomaterials 2011, 32:4336–4346.
112 Johansson, EMV, Crusz, SA, Kolomiets, E, Buts, L, Kadam, RU, Cacciarini, M, Barteles, KM, Diggle, SP, Cámara, M, Williams, P, Loris, R, Nativi, C, Rosenau, F, Jaeger, KE, Darbre, T, Reymond, JL. Inhibition and dispersion of
Pseudomonas aeruginosa biofilms by glycopeptide dendrimers targeting the fucose‐specific lectin LecB. Chem Biol 2008, 15:1249–1257.
113 Kolomiets, E, Swiderska, MA, Kadam, RU, Johansson, EMV, Jaeger, KE, Darbre, T, Reymond, JL. Glycopeptide dendrimers with high affinity for the fucose‐binding lectin LecB from
Pseudomonas aeruginosa. ChemMedChem 2009, 4:562–569.
114 Kadam, RU, Bergmann, M, Hurley, M, Garg, D, Cacciarini, M, Swiderska, MA, Nativi, C, Sattler, M, Smyth, AR, Williams, O, Cámara, M, Stocker, A, Darbre, T, Reymond, JL. A glycopeptide dendrimer inhibitor of the galactose‐specific lectin LecA and of
Pseudomonas aeruginosa biofilms. Angew Chem Int Ed Engl 2011, 50:10631–10635.
115 Ortega, P, Copa‐Patiño, JL, Muñoz‐Fernández, A, Soliveri, J, Gomez, R, de la Mata, FJ. Amine and ammonium functionalization of chloromethylsilane‐ended dendrimers. Antimicrobial activity studie. Org Biomol Chem 2008, 6:3264–3269.
116 Murugan, E, Vimala, G. Effective functionalization of multiwalled carbon nanotube with amphiphilic poly(propyleneimine) dendrimer carrying silver nanoparticles for better dispersability and antimicrobial activity. J Colloid Interface Sci 2011, 357:354–365.
117 Wang, B, Navath, RS, Menjoge, AR, Balakrishnan, B, Bellair, R, Dai, H, Romero, R, Kannan, S, Kannan, RM. Inhibition of bacterial growth and intramniotic infection in a guinea pig model of chorioamnionitis using PAMAM dendrimers. Int J Pharm 2010, 395:298–308.
118 Patrick, LA, Gaudet, LM, Farley, AE, Rosssiter, JP, Tomalty, LL, Smith, GN. Development of a guinea pig model of chorioamnionitis and fetal brain injury. Am J Obstet Gynecol 2004, 191:1205–1211.
119 Arnold, TM, Dotson, E, Sarosi, GA, Hage, CA. Traditional and emerging antifungal therapies. Proc Am Thorac Soc 2010, 7:222–228.
120 Wiebe, V, Karriker, M. Therapy of systemic fungal infections: a pharmacologic perspective. Clin Tech Small Anim Pract 2005, 20:250–257.
121 Tulu, M, Aghatabay, NM, MSenel, M, Dizman, C, Parali, T, Dulger, B. Synthesis, characterization and antimicrobial activity of water soluble dendritic macromolecules. Eur J Med Chem 2009, 44:1093–1099.
122 Janiszewska, J, Sowińska, A, Rajnisz, A, Solecka, J, Łącka, I, Milewski, S, Urbańczyk‐Lipkowska, Z. Novel dendrimeric lipopeptides with antifungal activity. Bioorg Med Chem Lett 2012, 22:1388–1393.
123 Latgé, JP. The cell wall: a carbohydrate armour for the fungal cell. Mol Microbiol 2007, 66:279–290.
124 Mishra, MK, Kotta, K, Hali, M, Wykes, S, Gerard, HC, Hudson, AP, Whittum‐Hudson, JA, Kannan, RM. PAMAM dendrimer‐azithromycin conjugate nanodevices for the treatment of
Chlamydia trachomatis infections. Nanomed Nanotech Biol Med 2011, 7:935–944.
125 Durairaj, C, Kadam, RS, Chandler, JW, Hutcherson, SL, Kompella, UB. Nanosized dendritic polyguanidilyated translocators for enhanced solubility, permeability, and delivery of gatifloxacin. Invest Ophthalmol Vis Sci 2010, 51:5804–5816.
126 Winnicka, K, Wroblewska, M, Wieczorek, P, Sacha, PT, Tryniszewska, E. Hydrogel of ketoconazole and PAMAM dendrimers: formulation and antifungal activity. Molecules 2012, 17:4612–4624.
127 Ma, M, Cheng, Y, Xu, Z, Xu, P, Qu, H, Fang, Y, Xu, T, Wen, L. Evaluation of polyamidoamine (PAMAM) dendrimers as drug carriers of anti‐bacterial drugs using sulfamethoxazole (SMZ) as a model drug. Eur Med Chem 2007, 42:93–98.
128 Strydom, SJ, Rose, WE, Otto, DP, Liebenberg, W, de Villiers, MM. Poly(amidoamine) dendrimer‐mediated synthesis and stabilization of silver sulfonamide nanoparticles with increased antibacterial activity. Nanomed Nanotech Biol Med 2012, doi:10.1016/j.nano.2012.03.006.
129 Chen, X, Zhang, M, Zhou, C, Kallenbach, NR, Ren, D. Control of bacterial persister cells by Trp/Arg‐containing antimicrobial peptides. Appl Environ Microbiol 2011, 77:4878–4885.
130 Balaban, NQ. Persistence: mechanisms for triggering and enhancing phenotypic variability. Curr Opin Genet Dev 2011, 21:768–775.
131 Fauvart, M, De Groote, VN, Michiels, J. Role of persister cells in chronic infections: clinical relevance and perspectives on anti‐persister therapies. J Med Microbiol 2011, 60:699–709.
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
